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The aim of this study was to characterize three batches of albendazole by pharmacopeial and 
complementary analytical techniques in order to establish more detailed specifications for the development 
of pharmaceutical forms. The ABZ01, ABZ02, and ABZ03 batches had melting points of 208 °C, 208 °C, 
and 209 °C, respectively. X-ray diffraction revealed that all three batches showed crystalline behavior and 
the absence of polymorphism. Scanning electron microscopy showed that all the samples were crystals 
of different sizes with a strong tendency to aggregate. The samples were insoluble in water (5.07, 4.27, 
and 4.52 mg mL-1, respectively) and very slightly soluble in 0.1 M HCl (55.10, 56.90, and 61.70 mg mL-1, 
respectively) and additionally showed purities within the range specified by the Brazilian Pharmacopoeia 
5th edition (F. Bras. V; 98% to 102%). The pharmacopeial assay method was not reproducible and some 
changes were necessary. The method was validated and showed to be selective, specific, linear, robust, 
precise, and accurate. From this characterization, we concluded that pharmacopeial techniques alone 
are not able to detect subtle differences in active pharmaceutical ingredients; therefore, the use of other 
complementary techniques is required to ensure strict quality control in the pharmaceutical industry.
Uniterms: Albendazole/characterization. Antiparasitics/quality control.
O objetivo do trabalho foi caracterizar três lotes de albendazol com técnicas analíticas farmacopéicas e 
complementares a fim de estabelecer especificações mais detalhadas para o desenvolvimento de formas 
farmacêuticas. Os lotes ABZ01, ABZ02 e ABZ03 apresentaram fusão em 208 °C, 208 °C e 209 °C. Foi 
possível evidenciar, por difração de raios X, que os três lotes apresentaram comportamento cristalino 
e ausência de polimorfismo. Através da microscopia eletrônica de varredura verificou-se que todas as 
amostras apresentaram cristais com diferentes tamanhos e forte tendência de agregação. As amostras 
foram insolúveis em água (5,07; 4,27 e 4,52 µg mL-1) e muito pouco solúveis em HCl 0,1M (55,10; 
56,90 e 61,70 µg mL-1) e, ainda, apresentaram pureza dentro da faixa especificada pela F.Bras.V (98% 
a 102%). O método farmacopéico de doseamento não foi reprodutível, e algumas mudanças foram 
necessárias. O método foi validado e demonstrou ser seletivo, específico, linear, robusto, preciso e exato. 
A partir dessa caracterização, pode-se concluir que apenas técnicas farmacopéicas não são capazes de 
detectar diferenças sutis entre os ingredientes farmacêuticos ativos, necessitando, portanto, de uso de 
outras técnicas complementares para garantir um rígido controle de qualidade na indústria farmacêutica.
Unitermos: Albendazol/caracterização. Antiparasitários/controle de qualidade.
INTRODUCTION
 Characterization of the physical and physico-
chemical properties of drugs is essential for the develop-
ment of pharmaceutical forms and is the first step in the 
drug design process. Changes in the active pharmaceutical 
ingredient (API) may impair productivity, affect product 
quality, and even cause the loss of a production batch 
(Nery et al., 2008; Soares Sobrinho et al., 2010).
Albendazole (ABZ; methyl-5-propylthio-2-benz-
imidazolecarbamate; Figure 1), a member of the benz-
imidazole family of compounds, is a crystalline white 
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odorless powder that melts at 207 °C–209 °C. It has a 
molecular weight of 265.34 g mol-1 and the molecular 
formula is C12H15N3O2S. In the Biopharmaceutical Clas-
sification System (BCS), it is a Class II substance, with 
low solubility and high permeability (Merck Index, 1996; 
Lindenberg et al., 2004).
The molecule was patented in 1975 but there were 
no reports available regarding its solid-state characteriza-
tion or possible polymorphisms. In 2010, Pranzo et al. 
showed that the re-crystallization of ABZ from methanol 
and N,N-dimethylformamide affords a new stable poly-
morphic form (Form II), enantiotropically related to the 
commercially available ABZ.
ABZ is the API most widely used for controlling in-
testinal parasites, because it has broad-spectrum activity, is 
well tolerated, and has low cost (Moriwaki et al., 2008). Ac-
cording to the National Health Surveillance Agency (AN-
VISA), the reference drug is Zentel® (GlaxoSmithKline), 
and currently, there are 11 types of generic medications from 
several pharmaceutical laboratories in Brazil. ABZ is avail-
able in the form of 200 mg tablets, 400 mg chewable tablets, 
and a 400 mg10 mL-1 oral suspension (ANVISA, 2010).
Knowing that ABZ is a class II (BCS) substance and 
considering that the presence of polymorphic forms could 
cause changes in the melting point, density, solubility, dis-
solution, physical or chemical stability, and consequently 
drug bioavailability, it is extremely important to obtain 
in-depth knowledge of the drug, if the required pharma-
copeial tests are not enough to identify subtle differences 
among the raw materials, especially in pre-formulation 
studies, thereby threatening the quality of the product. 
Thus, it is very important to use different parameters, e.g., 
melting point, and techniques, e.g., infrared spectroscopy 
and X-ray diffraction, for characterization (Nery et al., 
2008; Storpirtis et al., 2009; Maximiano, 2010).
Therefore, the aim of this study was to evaluate 
the physical and physicochemical characteristics of ABZ 
through different identification and characterization tests, 
as a way to establish quality standards and aid technologi-
cal improvements in this antiparasitic drug.
MATERIAL AND METHODS
ABZ was provided by Formil Química® (Barueri, 
Brazil),  batches 1005024006, 1005022006, and 
1002008006, which for the proposed study were identi-
fied as ABZ01, ABZ02, and ABZ03, respectively. Pharma-
copeial Standard Batch 1034, content (99.80%) INCQS, 
Rio de Janeiro, Brazil. All solvents and reagents used 
in the trials were of analytical grade, the glassware was 
calibrated, and the tests described below were performed 
in 3 replicates.
To improve understanding, the analyses were clas-
sified as pharmacopeial and non-pharmacopeial (comple-
mentary), owing to some discriminative characteristic 
methods cited in the Brazilian Pharmacopoeia 5th edition 
(F. Bras. V, 2010).
PHARMACOPEIAL TESTS
Organoleptic characterization
Organoleptic characteristics were compared to those 
described in the F. Bras. V (2010) and Drug Master File 
(DMF) for the API provided by Formil Química®.
Infrared spectroscopy
Infrared spectroscopy with a KBr tablet was verified 
using a Fourier Transformed Infrared Spectrometer (model 
IFS66, Bruker, Madison, WI, USA). The spectrum of the 
API was drawn in the range of 4000 cm-1 to 400 cm-1 ac-
cording to the method described in the F. Bras. V (2010).
Melting point
The melting point was evaluated using a Mars´ 
Fusiometer, model III, in accordance with the general 
method of F. Bras. V (2010) and by differential thermal 
analysis (DTA).
Assay
Initially, 40 mg of ABZ was weighed into a 50 mL 
round-bottomed volumetric flask; 37% HCl was added to 
10% of the flask volume; and then the volume was made 
up with methanol from a stock solution (concentration, 
800 μg mL-1). The solution was shaken with a magnetic bar 
for 5 min and subjected to dispersion in an ultrasonic bath 
for a further 5 min. To evaluate the content, an analytical 
curve was used, in triplicate, with concentrations of 60, 80, 
120, 180, 320 μg mL-1, generated by dilution of the stock 
solution in monobasic sodium phosphate/methanol (40:60) 
buffer and analyzed by high-performance liquid chroma-
tography coupled with an ultraviolet detector (HPLC-UV) 
FIGURE 1 - Chemical structure of albendazole.
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set at 308 nm. The concentration of 120 μg mL-1 was 
considered 100%.
The chromatographic conditions were as fol-
lows: stationary phase: Luna 5 μm C18 column, 100 Å, 
250 × 4.6 mm; mobile phase: monobasic sodium phos-
phate/methanol buffer (40:60), pH 4.8, isocratic; flow rate: 
2.0 mL min-1; detector: UV (308 nm), Temperature: 40 ºC, 
and injection volume: 20 mL.
The validation process was performed according to 
the present guidelines contained in Resolution RE-899 
passed on May 29, 2003 (ANVISA, 2003). To evaluate 
selectivity and specificity, 3 standard and placebo batches 
were used at the working concentration (120 µg mL-1 = 
100% theoretical concentration). Linearity was obtained 
from a standard calibration curve, in triplicate, with 5 
standard solutions at concentrations corresponding to 60, 
80, 120, 160, and 320 µg mL-1, expressed by the correla-
tion coefficient obtained through the least squares method. 
Precision was evaluated based on repeatability, i.e., 
correlation between results obtained within a short period 
of time using the same instrumentation and analyst. Six 
analytical solutions of the sample were used at the working 
concentration (120 µg mL-1 = 100% theoretical concentra-
tion) and for intermediate precision methods, batches in 
triplicate at the same working concentration were used, on 
different days by different analysts. 
For accuracy, we used samples in triplicate, at concen-
trations equivalent to 60, 120, and 180 µg mL-1, correspond-
ing to 50%, 100%, and 150% of the theoretical concentra-
tion of the tested drug, ABZ. Robustness was evaluated by 
varying parameters such as the manufacturer of methanol 
and shaking time (5 and 10 min). The results were analyzed 
using analysis of variance (ANOVA), relative standard de-
viation, or coefficient of variation and Student t-test. 
Solubility
Solubility studies were performed using a large quan-
tity of drug in 25 mL of 2 liquids (water and 0.1 M HCl). 
ABZ samples were initially submitted to ultrasound disper-
sion for 5 min and placed under magnetic stirring at 25 °C 
(±2 °C) for 24 h. They were then submitted to centrifugation 
at 3000 rpm for 30 min, and a 100 µL sample was taken from 
the supernatant, diluted to 10 mL, filtered (0.22 μm), and 
measured by HPLC-UV with detection at 308 nm.
COMPLEMENTARY TESTS
Nuclear Magnetic Resonance Spectroscopy
In order to complement the identification of raw 
materials, nuclear magnetic resonance (NMR) analyses 
were performed. Proton (1H) and Carbon-13 (13C) NMR 
experiments were performed on a Varian® spectrometer, 
model Unity plus-300 MHz (Palo Alto, CA), using di-
methyl sulfoxide as the solvent.
Flow properties
Density was determined by testing 20 g of each 
sample using an automatic compactor (Tapped Density 
Tester Varian 50-100) equipped with a calibrated cylin-
der. The initial volume of the sample was verified and 10 
compressions were performed for powder accommoda-
tion. Then, 1250 compressions were done. The relation-
ship between the mass (g) and the volume (mL) occupied 
by the powder before and after compression determined 
the apparent density (ApD) and the compression density 
(CpD), respectively. The Hausner index (HI) and the Carr 
index (CI) were calculated using the following equations: 
HI = ApD/CpD and CI = (CpD – ApD)/CpD × 100 (USP, 
2007; Soares Sobrinho et al., 2008; Alves et al., 2008).
The angle of repose was measured using a protractor 
from the conical pile of powder formed by the flow of the 
API through a funnel of standardized dimensions on a flat 
surface. Flow time was determined by measuring the time 
required to drain 30 g of the API through a standardized 
funnel, using a digital stopwatch (Carini et al., 2009).
X-ray diffraction
X-ray diffraction analysis (XRD) was performed 
using a model D5000 diffractometer (Siemens, Munich, 
Germany) with an operating current of 40 mA, under a 
40 kV tension, traversing the region between 2° and 40° 
(2θ) (Alanazi et al., 2007; Lopes, 2007).
Granulometric and crystal morphology analysis
Morphological analysis of ABZ particles was car-
ried out by scanning electron microscopy (SEM), with a 
SS-550 microscope (Shimadzu, Kyoto, Japan), a working 
distance (WD) of 13 mm, and 800-, 4500- and 15000-fold 
magnification. Samples were previously metalized with a 
25-nm thick layer of gold for a duration of 2.5 min (Quick 
Coater´s Sputter, model SC701, Sanyu Electron, Tokyo, 
Japan).
Particle size distribution was determined by sieving 
30 g of the material through standardized and superim-
posed Bertel® sieves (20, 40, 60, 80, and 100 mesh) for 
20 min (Medeiros, 2010). Another technique applied was 
particle size distribution by laser diffraction and photon 
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correlation spectroscopy (PCS), in a DelsaTM Nano-S Par-
ticle Analyzer (Beckman Coulter, Brea, CA) at 25 ºC with 
a detection angle of 90º. A dispersion of 12 mg of ABZ in 
20 mL of a 0.02% (v/v) aqueous solution of the surfactant 
Tween 80 was kept in an ultrasonic bath (40 KHz) for 1 
min. Due to the hydrophobicity, a tensoactive agent was 
used to facilitate particle dispersion. The results are re-
ported in terms of average size ± standard deviation.
Thermal characterization
Thermogravimetric analysis (TG) and DTA were 
performed for all 3 batches of ABZ.
TG and DTA were conducted using a thermal bal-
ance, model TGA Q60 (Shimadzu) in an atmosphere 
with a nitrogen flow of 50 mL min-1. The sample weight 
was around 3 mg (±0.3), placed in a platinum crucible 
at a temperature range of 30 °C to 600 °C and a heating 
rate of 10 °C min-1. Prior to the tests, the instrument was 
calibrated using a sample of aluminum and zinc (Aulton, 




All three batches ABZ01, ABZ02, and ABZ03 were 
white crystalline to pale yellowish powders with a charac-
teristic odor, consistent with the characteristics described 
in the F. Bras. V (2010) and DMF.
Infrared spectroscopy
The infrared spectra of ABZ01, ABZ02, and ABZ03 
were similar, with the presence of absorption bands at 
3390.32 cm-1, representing the amide NH bond, and at 
1711.71 cm-1, representing the ester C=O bond, corre-
sponding to the carbamate portion of the ABZ molecule. 
Another absorption band appears at 1622.06 cm-1, repre-
senting the aromatic C=C bond, corresponding, along with 
the amide NH bond, to the benzimidazole portion of the 
ABZ molecule. Additionally, the absorption bands from 
the aliphatic hydrocarbon group at 2959.32 cm-1, the ether 
bond at 1096.12 cm-1, the C-H bond at 1622.06 cm-1, and 
the S=C bond at 1096.12 cm-1 confirm the authenticity of 
the API. The infrared spectrum from ABZ01 is represented 
in Figure 2.
Melting point
The measured melting points of the 3 batches, 
ABZ01, ABZ02, and ABZ03, were 208 °C, 208 °C, and 
209 °C, respectively, and based on DTA analysis, these 
values were 209.27 °C, 209.89 °C, and 209.60 °C, respec-
tively; both techniques yielded results in accordance with 
the F. Bras. V (2010) and DMF (Table I).
Assay
The pharmacopeial method was not reproducible 
because it presented differing results with variations above 
5.0% for each batch; therefore, it was necessary to make 
changes in the method to achieve better results. These 
changes resulted in a good method with reproducible results, 
in accordance with the F. Bras. V (98% to 102%) (Table I).
The validated method showed selectivity and speci-
ficity, and there was no significant interference from other 
components (placebo) when compared with the standard 
samples. The calibration curve of ABZ was linear (y = 
593976x + 2E+06) with a correlation coefficient (R2) of 
0.99, the minimum acceptable criterion (Figure 3).
The method showed repeatability in all 6 standard 
batches, with a relative standard deviation (RSD) of 
1.44%, within the 5% permitted by RE 899/2003. The 
method also demonstrated intermediate precision when 





ABZ01 208 209.27 99.74% ± 0.21%
ABZ02 208 209.89 100.01% ± 0.12%
ABZ03 209 209.60 99.89% ± 0.59%
FIGURE 2 - Infrared spectrum of ABZ01 and its absorption 
bands.
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tested on different days by different analysts; there were 
no statistically significant differences between results 
obtained by different analysts and on different days, using 
the Student t-test. The calculated t was 1.25, 0.37, 0.05, 
and 1.01 between analysts on day 1, between analysts on 
day 2, between days for analyst 1, and between days for 
analyst 2, respectively, with all values lower than the criti-
cal t (2.13), with 95% confidence. 
The results for accuracy were close to 100%, with 
coefficients of variation (CVs) of 0.13%, 0.013%, and 
0.07% for the theoretical concentrations of 50%, 100%, 
and 150%, respectively, according to Table II.
In the robustness test (Table III), when the manu-
facturer of methanol was changed, the calculated t value 
(2.03) was lower than the critical t value (2.91); similarly, 
when varying the shaking time (5 and 10 min), the cal-
culated t value (1.92) was lower than the critical t value 
(2.91). Thus, there were no statistically significant dif-
ferences (Student t-test) with 95% confidence and this 
TABLE II - Results for accuracy in 3 concentrations (60, 120, and 180 µg mL-1) in triplicate, corresponding to 50%, 100%, and 
150% according to RE 899⁄03
Determinations 60 µg mL-1 % 120 µg mL-1 % 180 µg mL-1 %
1 60.49 100.82 119.52 99.60 179.71 99.84
2 60.65 101.08 119.50 99.58 179.56 99.75
3 60.61 101.02 119.48 99.57 179.81 99.89




Sample 1 Sample 2 Sample 3
Methanol A 120.77 121.77 120.26 120.93 0.63
Methanol B 120.26 120.09 119.91 120.08 0.14
Shaking time 5 min 120.88 120.24 119.89 120.30 0.41
Shaking time 10 min 121.86 120.82 120.93 120.97 0.46
FIGURE 3 - Calibration curve of ABZ.
method can therefore be considered robust.
Therefore, this validated method was demonstrated 
to be selective, specific, linear, robust, precise, and ac-
curate, providing the reliability required for an analytical 
method to be eligible for application in routine quality 
control laboratories.
Solubility
The 3 batches ABZ01, ABZ02, and ABZ03 showed 
aqueous solubilities of 5.07, 4.27, and 4.52 µg/mL (clas-
sified as insoluble), and in 0.1 M HCl solution presented 
solubilities of 55.10, 56.90, and 6170 µg/mL, respectively 
(classified as very slightly soluble), according to F. Bras. 
V (2010).
Complementary Tests
Nuclear Magnetic Resonance Spectroscopy
1H NMR data revealed a triplet at 0.95 and 2.85 
ppm and a multiplet at 1.54, corresponding to protons of 
alkyl groups. Further, the presence of a doublet at 7.33 
and 7.11 ppm and a singlet at 7.44 ppm (corresponding to 
aromatic protons) as well as that of a doublet at 3.76 ppm 
(corresponding to the 3H of a carbamate group) and at 
11.67 ppm (corresponding to a proton of the amino group) 
was also confirmed. The NMR 13C chemical shifts indicate 
the presence of aliphatic carbons in the chemical shifts at 
39.50, 21.98, and 12.88 ppm, aromatic carbons at 135.29, 
114.00, 123.97, 126.87, 115.73, and 136.65 ppm, and 
carbonyl at 154.69 ppm. The chemical structure of ABZ 
is therefore confirmed through peaks, absorption, and the 
characteristic fragmentation of the molecule.
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Flow properties
The bulk densities of ABZ01, ABZ02, and ABZ03 
were 0.257 g mL-1, 0.264 g mL-1, and 0.256 g mL-1, 
respectively; and the compressed densities were 0.408 
g mL-1, 0.420 g mL-1, and 0.400 g mL-1, respectively. The 
CI indicates the powder compression capacity; for values 
between 5% and 15%, the powder is considered to have 
excellent flow, and above 21%, it is considered to have 
low flow and compression. Since the CI values for ABZ01, 
ABZ02, and ABZ03 were 35.24, 37.89, and 35.83, respec-
tively, the powder is classified as low flow. The HI is also 
a measure of flow; values smaller than 1.25 indicate good 
flow, values higher than 1.5 indicate poor flow, and values 
between 1.25 and 1.5 indicate that lubricants are required 
to improve drainage. The HI values for ABZ01, ABZ02, 
and ABZ03 were 1.57, 1.63, and 1.55, respectively, thus 
classifying them as poor-flow powders (Alves et al., 2008).
The angle of repose technique and flow time con-
firmed the poor flow of ABZ powder, since there was no 
flow (Alves et al., 2008). Based on all these results from 
powder rheology, ABZ can be classified as a poor-flow 
powder, and these findings are of great importance for 
the pre-formulation study required in drug development 
(Medeiros, 2010).
Results were evaluated statistically by the Student 
t-test and no statistically significant differences were 
observed at the 95% confidence level, between batches 
ABZ01 and ABZ03. However, some differences were seen 
in batch ABZ02: the bulk density, compressed density, CI, 
and HI values were consistently slightly higher.
X-ray diffraction
Results of XRD analysis for ABZ01, ABZ02, and 
ABZ03 can be seen in the diffractogram below (Figure 4), 
with the presence of higher repetitive peaks at 2θ around 
7.3°, 11.8°, 20.4°, and 24.7°, indicating crystalline be-
havior of all 3 batches ABZ01, ABZ02, and ABZ03. Con-
sistent with Pranzo et al., (2010), the 3 batches (ABZ01, 
ABZ02, and ABZ03) were not Form II polymorphs.
However, this result can be used to confirm the ab-
sence of polymorphs in the 3 batches only when coupled 
with findings of differential scanning calorimetry (DSC) 
techniques in different atmospheres and temperatures and 
TG/DTG (Storpirtis et al., 2009).
Granulometric and crystal morphology analysis
Figure 5 displays the results of particle distribution 
by the sieving method. Powders are described in pharma-
copeia as coarse or fine, and the differentiation is made 
and expressed in terms of the aperture size of the sieve 
mesh used (Medeiros, 2010; Aulton, 2005). The F. Bras. V 
(2010) describes the following classification: coarse par-
ticles entirely pass through a sieve with a nominal mesh 
opening of 1700 μm; moderately coarse particles pass 
through a 710-μm mesh sieve; moderately fine, fine, and 
very fine particles pass through 355-μm, 180-μm, and 
125-μm mesh sieves, respectively.
The granulometric distribution (Figure 5) showed 
that 59% of ABZ01 particles and 62% of ABZ03 particles 
were retained in the 250-µm sieve, and so they are consid-
ered moderately coarse powders, while for ABZ02, 26% 
of all particles were retained in the 850-µm sieve, 25% 
FIGURE 4 - Diffractogram of ABZ01, ABZ02, and ABZ03.
FIGURE 5 - Granulometric distributions of ABZ01, ABZ02, 
and ABZ03.
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were retained in the 250-µm sieve and 33% in the 180-µm 
sieve, showing a totally non-uniform granulometric dis-
tribution that was different from those of batches ABZ01 
and ABZ03.
Another method used for particle size evaluation 
was laser diffraction. A comparative analysis of the aver-
age diameters for different percentage populations (10%, 
50%, and 90% of particles) obtained from the ABZ01, 
ABZ02, and ABZ03 batches is summarized in Table IV.
Batches ABZ01 and ABZ03 had a very similar par-
ticle size distribution, and it was observed that the average 
particle diameter for batches ABZ01 and ABZ03 were 
2.65 μm and 2.70 μm, respectively. However, the batch 
ABZ02 had a lower average particle size (1.74 μm) and 
is therefore more micronized. According to the DMF of 
albendazole, 90% of all particles are smaller than 20 μm; 
the results obtained using the laser diffraction technique 
are in accordance with the DMF, but the results from 
granulometric distribution by sieving are divergent.
TABLE IV - Particle sizes of the 3 batches of ABZ
Batches Average diameter 
(μm)
Average diameter 10% 
(μm)*
Average diameter 50% 
(μm)*
Average diameter 90% 
(μm)*
ABZ 01 2.65 ± 0.06 1.25 ± 0.14 3.83 ± 0.19 12.81 ± 2.12
ABZ 02 1.74 ± 0.10 0.98 ± 0.09 2.15 ± 0.10 4.97 ± 0.93
ABZ 03 2.70 ± 0.11 1.54 ± 0.15 4.88 ± 0.68 15.78 ± 2.59
*Population of particles (%) with a diameter lower than the expressed.
Therefore, there is a need to choose the best tech-
nique. Since the DMF is the identity of the API, the 
chosen technique is probably laser diffraction due to the 
similar results; however, this is not described in official 
compendia, and further investigations that may facilitate 
the quality control of APIs are needed.
With regard to albendazole, strict particle size con-
trol is needed, since this physical parameter can change the 
effectiveness of the pharmaceutical form and has a direct 
influence on its dissolution rate (Storpirtis et al., 2009). 
Crystal morphology analysis by SEM (Figure 6) 
showed uniformity among the 3 batches, ABZ01, ABZ02 
and ABZ03, and a crystalline structure in accordance to 
the XRD diffractogram, with crystals of different sizes and 
shapes showing a strong tendency to aggregate (Pranzo et 
al., 2010).
Thermal characterization
We verified the thermal profiles of the 3 batches, 
FIGURE 6 - Crystal morphologies of ABZ01, ABZ02, and ABZ03.
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ABZ01, ABZ02, ABZ03, using TG/DTG and DTA curves.
The DTA curve (Figure 7) showed an endother-
mic melting event. The melting temperatures (Tpeak) and 
energies for batches ABZ01, ABZ02, and ABZ03 were 
209.27 °C and 300.26 J/g, 209.89 °C and 311.97 J/g, and 
209.60 °C and 314.55 J/g, respectively, confirming the 
results of the pharmacopeial method as well as the results 
obtained with the melting point apparatus.
TG/DTG curves (Figure 8) showed that the first 
stage of moisture loss occurred at a temperature range 
of 30 °C–105 °C, and a mass loss of 0.78%, 1.22%, and 
2.08% for ABZ01, ABZ02, and ABZ03, respectively; 
these results do not interfere in the measurements of aque-
ous and 0.1 M HCl solubility.
We also verified 4 other decomposition stages for 
the batches ABZ01, ABZ02, and ABZ03. The first stage 
began between 197.22 °C and 205.94 °C with a mass 
loss of 3.70% to 4.13%; the second stage began between 
219.22 °C and 243.03 °C, with a mass loss of 9.33% to 
10.85%; the third stage began between 319.50 °C and 
349.00 °C with a mass loss of 15.41% to 16.25%; and the 
last stage began between 372.21 °C and 399.59 °C, with 
a mass loss of 25.45% to 28.43%.
CONCLUSION
The present study was of great importance to gather 
crucial information on the physical and physicochemical 
FIGURE 7 - Thermal profile of the 3 batches ABZ01, ABZ02, ABZ03 based on DTA curves.
FIGURE 8 - Thermal profile of the 3 batches, ABZ01, ABZ02, and ABZ03, based on TG/DTG curves.
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characteristics of ABZ, with the aim of facilitating better 
pharmacotechnical monitoring of the drug and improving 
routine quality control in the pharmaceutical industry.
It is observed that pharmacopeial techniques alone 
are not sufficient to identify differences in batches. 
Complementary techniques are more sensitive and dis-
criminating, making it possible to obtain more precise 
information on the API, thereby ensuring batch-to-batch 
standardization.
Therefore, it is necessary to include scientific foun-
dations for the development of quality control assays for 
the tested API, ABZ, to provide insights into its physico-
chemical properties, which can be used as a reference for 
other studies. This will allow the acquisition of knowledge 
that can be systematically used in the investigation and 
characterization of other therapeutic classes of APIs.
 Thus, for quality evaluation of ABZ and other 
APIs, it is also necessary to evaluate many quality control 
techniques in order to establish limits with well-defined 
specifications for parameters such as identification (in-
frared spectroscopy, NMR, and dosing) and other charac-
terization techniques (particle size, density, and thermal 
analysis).
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